2-(Substituted phenyl)amino analogs of 1-methoxyspirobrassinol methyl ether: Synthesis and anticancer activity

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 10, 2009, Pages 3698-3712

  Kutschy, Peter ^a   Salayová, Aneta ^a   Čurillová, Zuzana ^a   Kožár, Tibor ^b   Mezencev, Roman ^c   Mojžiš, Ján ^a   Pilátová, Martina ^a   Balentová, Eva ^a   Pazdera, Pavel ^d   Sabol, Marián ^a   Zburová, Michaela ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL PHYSICS   (Slovakia)

^c Georgia Institute of Technology   (United States)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Anticancer activity; Phytoalexins; QSAR; Spiroindolines

Indexed keywords

1 METHOXY 2 (2 CHLOROPHENYLAMINO) 2' (METHYLSULFANYL) SPIRO(INDOLINE 3,5' [4',5']DIHYDROTIAZOLE); 1 METHOXY 2 (4 BROMOPHENYLAMINO) 2' (METHYLSULFANYL) SPIRO(INDOLINE 3,5' [4',5']DIHYDROTIAZOLE); 1 METHOXY 2 (4 CHLOROPHENYLAMINO) 2' (METHYLSULFANYL) SPIRO(INDOLINE 3,5' [4',5']DIHYDROTIAZOLE); 1 METHOXY 2 (4 METHOXYPHENYLAMINO) 2' (METHYLSULFANYL) SPIRO(INDOLINE 3,5' [4',5']DIHYDROTIAZOLE); 1 METHOXYBRASSININ; 1 METHOXYSPIROBRASSININ; 1 METHOXYSPIROBRASSINOL; 1 METHOXYSPIROBRASSINOL METHYL ETHER DERIVATIVE; ANTINEOPLASTIC AGENT; BRASSININ; CAMALEXIN; CISPLATIN; CYCLOBRASSININ; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; INDOLE DERIVATIVE; NATURAL PRODUCT; PHYTOALEXIN; SPIRO COMPOUND; SPIROBRASSININ; SPIROINDOLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BRASSICACEAE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL STRAIN MCF 7; CRUCIFERA; DIASTEREOISOMER; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STREPTOCOCCUS PYOGENES;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM; TERPENES;

EID: 65349101121     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.03.064     Document Type: Article

References (35)

1. Gross D. J. Plant Dis. Prot. 100 (1993) 433
2. Pedras M.S.C., Okanga F.I., Zaharia I.L., and Khan A.Q. Phytochemistry 53 (2000) 161
3. Pedras M.S.C., Jha M., and Ahiahonu P.W.K. Curr. Org. Chem. 7 (2003) 1635
4. Mezencev R., Mojžiš J., Pilátová M., and Kutschy P. Neoplasma 50 (2003) 239
5. Pedras M.S.C., Zheng Q.A., and Sarma-Mamillapalle V.K. Nat. Prod. Commun. 2 (2007) 319
6. Mehta R.G., Liu J.F., Constantinou A., Hawthorne M., Pezzuto J.M., Moon R.C., and Moriarty R.M. Anticancer Res. 14 (1994) 1209
7. Mehta R.G., Liu J.F., Constantinou A., Thomas C.F., Hawthorne M., You M., Gerhauser C., Pezzuto J.M., Moon R.C., and Moriarty R.M. Carcinogenesis 16 (1995) 399
8. Sabol M., Kutschy P., Siegfried L., Miroššay A., Suchý M., Hrbková H., Dzurilla M., Marušková R., Starková J., and Paulíková E. Biologia 55 (2000) 701
9. Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová Z., Suchý M., Monde K., Mirossay L., and Mojžiš J. Leukemia Res. 29 (2005) 415
10. Moody C.J., Roffey J.R.A., Stephens M.A., and Stratford I.J. Anti-Cancer Drugs 8 (1997) 489
11. Monde K., Takasugi M., and Shirata A. Phytochemistry 39 (1995) 581
12. Monde K., Taniguchi T., Miura N., Kutschy P., Čurillová Z., Pilátová M., and Mojžiš J. Bioorg. Med. Chem. 13 (2005) 5206
13. For the definition of cis- and trans-diastereoisomers see:. Čurillová Z., Kutschy P., Budovská M., Nakahashi A., and Monde K. Tetrahedron Lett. 48 (2007) 8200
14. Mezencev R., Kutschy P., Salayová A., Čurillová Z., Mojžiš J., Pilátová M., and McDonald J. Chemotherapy 54 (2008) 372
15. Galliford C.V., and Scheidt K.A. Angew. Chem., Int. Ed. 46 (2007) 8748
16. Kutschy P., Suchý M., Monde K., Harada N., Marušková R., Čurillová Z., Dzurilla M., Miklošová M., Mezencev R., and Mojžiš J. Tetrahedron Lett. 43 (2002) 9489
17. Kawasaki T., and Somei M. Heterocycles 31 (1990) 1605
18. Pedras M.S.C., and Zaharia I.L. Phytochemistry 55 (2000) 213
19. Topliss J.G. J. Med. Chem. 15 (1972) 1006
20. jaguar, version 7.0; Schrodinger, LLC: New York, NY, USA, 2008.
21. Finlay G.J., and Baguley B.C. Eur. J. Cancer Clin. Oncol. 20 (1984) 947
22. Baguley B.C., Hicks K.O., and Wilson W.R. Tumor Cell Cultures in Drug Development. In: Baguley B.C., and Kerr D.J. (Eds). Anticancer Drug Development (2002), Academic Press, San Diego 269-284
23. Baldwin E.L., and Osheroff N. Curr. Med. Chem. Anticancer Agents 5 (2005) 363
24. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., and Boyd M.R. J. Natl. Cancer Inst. 81 (1989) 1088
25. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., and Liu L.F. Science 226 (1984) 466
26. Yamori T. Cancer Chemother. Pharmacol. 52 (2003) S74
27. phase, version 3.0; Schrodinger, LLC: New York, NY, USA, 2008.
28. Dixon S.L., Smondyrev A.M., Knoll E.H., Rao S.N., Shaw D.E., and Friesner R.A. J. Comput. Aided Mol. Des. 20 (2006) 647
29. Evans D.A., Doman T.N., Thorner D.A., and Bodkin M.J. J. Chem. Inf. Model. 47 (2007) 1248
30. Discovery Studio Visualizer, v2.0; Accelrys Software Inc.: San Diego, USA, 2007.
31. Jorgensen W.L., and Duffy E.M. Adv. Drug Delivery Rev. 54 (2002) 355
32. Mosmann T. J. Immunol. Methods 65 (1983) 55
33. Isenberg, H. D. American Society for Microbiology, Clinical microbiology procedures handbook; American Society of Microbiology: Washington, DC, 1992.
34. Liu W., Liu X., Knaebel D., Luck L., and Li Y. Antimicrob. Agents Chemother. 42 (1998) 911
35. Betina V., and Mičeková D. Z. Allg. Mikrobiol. 12 (1972) 355